Active material: Ksilometazolin
When ATH: R01AA07
CCF: Vasoconstrictor drugs for local application in an ENT-practice
ICD-10 codes (testimony): H66, H68, J00, J01, J30.1, J30.3, Z51.4
When CSF: 24.05.01
Manufacturer: NOVARTIS CONSUMER HEALTH S.A. (Switzerland)
◊ Nasal drops (for children) 0.05% as a clear, colorless liquid, without smell.
| 1 ml | |
| Xylometazoline hydrochloride | 500 g |
Excipients: sodium dihydrogen phosphate dihydrate, sodium hydrogen phosphate dodecahydrate, disodium эdetat, benzalkonium chloride (in shape 50% solution), sorbitol 70%, гипромеллоза – 4 thous., sodium chloride, water.
10 мл – флаконы полиэтиленовые (1) complete with a cover-dropper, снабженной системой контроля первого вскрытия – пачки картонные.
Vasoconstrictor drugs for local application in an ENT-practice. Xylometazoline has alpha adrenomimeticheskim action. Causes vasoconstriction of the nasal mucosa, thus eliminating edema and hyperemia mucosa nasopharynx. Facilitates nasal breathing in rhinitis.
The drug is well tolerated by patients with sensitive mucosa, its effect does not interfere with the separation of mucus. The preparation has a balanced pH, characteristic of the nasal cavity. В состав препарата входят неактивные компоненты – сорбитол и гипромеллоза, which are moisturizers, to reduce the symptoms of dryness and irritation of the nasal mucosa, arising from prolonged use Xylometazoline.
At therapeutic concentrations does not irritate, It does not cause congestion.
The action comes after a few minutes after application and lasts for 12 no.
When applied topically, virtually not absorbed, plasma concentrations are so small, that they can not be determined by modern analytical methods.
- Acute respiratory infections with symptoms of rhinitis;
- Acute allergic rhinitis;
- Hay fever;
- Sinusitis;
- Evstahiit;
- Otitis media (to reduce swelling of the mucous membrane of the nasopharynx);
- Preparation of the patient for diagnostic procedures in the nasal passages.
Nasal drops prescribed infants and children under the age of 6 years by 1-2 drops in each nostril 1-2 times / day, should not be applied more 3 time / day; older children 6 years appoint 2-3 drops in each nostril 3-4 times / day.
Длительность применения – не более 10 days in a row.
Local reactions: at frequent and / or long-term use - irritation and / or dryness of the nasal mucosa, burning, pricking, chikhaniye, hypersecretion; rare - swelling of the nasal mucosa.
Systemic reactions: at frequent and / or long-term use - nausea; rarely - tachycardia, palpitations, arrhythmia, increased blood pressure, headache, dizziness, vomiting, insomnia, blurred vision, allergic reactions; long-term use at high doses - depression.
- Arterial hypertension;
- Tachycardia;
- Expressed atherosclerosis;
- Glaucoma;
- Atrophic rhinitis;
- Hyperthyroidism;
- Surgical interventions in the meninges (history);
- Hypersensitivity to the drug.
FROM caution is used in patients with diabetes, cardiovascular diseases, hypersensitivity to adrenergic drugs, accompanied by symptoms of insomnia, dizziness, cardiac arrhythmias, tremor, high blood pressure.
During pregnancy and lactation the drug should be used only after careful evaluation of the risks and benefits for mother and fetus, not to exceed the recommended doses.
Do not exceed the recommended dose and duration of use of the drug, especially in children and elderly patients.
When using the drug in children under 1 , the need to consult a doctor.
Children under the age of 6 years of the drug should be used under medical supervision.
Effects on ability to drive vehicles and management mechanisms
Xylometazoline does not affect the ability to drive vehicles and management mechanisms.
Symptoms: increased side effects (increased blood pressure, increased heart rate, иногда – спутанность сознания).
Treatment: symptomatic therapy.
Incompatible with MAO inhibitors and tricyclic antidepressants.
The drug is resolved to application as an agent Valium holidays.
The drug should be stored out of reach of children at or above 30 ° C. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More